Novo Seeds looks back at year of investment and innovation

12 January 2022
research_biotech_microscopes_lab_big

Novo Seeds, the early stage investment and company creation team of Novo Nordisk’s (NOV: N) primary shareholder, has provided a review of its activities in 2021.

The unit is a vehicle for a portion of the investments made by Novo Holdings, the owner of the unlisted A shares of the Danish diabetes giant. Established in 1999, Novo Holdings manages the assets of the Novo Nordisk Foundation, which are worth around $75 billion.

Spreading seeds

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology